Biktarvy

Name: Biktarvy
SKU: 9457
Availability: InStock

From: $950.00

Dosage

Clear

Quantity:

Description

Biktarvy is a fixed-dose combination antiretroviral medication that includes:

Bictegravir (BIC) – an integrase strand transfer inhibitor (INSTI) that blocks the integration of viral DNA into human cells.
Emtricitabine (FTC) – a nucleoside reverse transcriptase inhibitor (NRTI) that interferes with viral replication.
Tenofovir alafenamide (TAF) – a prodrug of tenofovir, also an NRTI, designed for strong antiviral activity with fewer kidney and bone side effects compared to older formulations.

This 3-in-1 combination provides a complete HIV regimen without the need for additional medications.

Treatment of HIV-1 infection in adults and children weighing ≥14 kg
For patients newly diagnosed with HIV or those switching from another regimen if they have no known resistance to the components

Bictegravir stops the HIV enzyme integrase from inserting viral DNA into host cells.
Emtricitabine and Tenofovir alafenamide block reverse transcriptase, an enzyme HIV needs to copy its RNA into DNA.
Together, these mechanisms suppress viral replication, reduce viral load to undetectable levels, and help maintain healthy immune function.

Single-tablet regimen – simplifies treatment with one pill per day.
High barrier to resistance – especially due to bictegravir.
Effective across diverse patient populations, including those with high baseline viral loads.
Fewer kidney and bone complications compared to older tenofovir-based therapies.
Well-tolerated with a favorable safety profile in most patients.